CRIS Current Research Information System

MARCONATO, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.808
NA - Nord America 8.128
AS - Asia 3.487
AF - Africa 301
SA - Sud America 66
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 7
Totale 25.816
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9.224
US - Stati Uniti d'America 8.088
GB - Regno Unito 1.395
CN - Cina 1.116
SG - Singapore 1.034
DE - Germania 913
VN - Vietnam 708
SE - Svezia 524
IN - India 432
FR - Francia 423
IE - Irlanda 299
UA - Ucraina 271
ZA - Sudafrica 187
RU - Federazione Russa 154
BG - Bulgaria 133
CH - Svizzera 69
TG - Togo 63
NL - Olanda 57
EE - Estonia 51
FI - Finlandia 50
BR - Brasile 46
ID - Indonesia 44
PL - Polonia 37
BE - Belgio 36
ES - Italia 35
GR - Grecia 32
CI - Costa d'Avorio 31
JO - Giordania 29
RO - Romania 25
TR - Turchia 24
CA - Canada 22
HK - Hong Kong 22
JP - Giappone 18
HR - Croazia 17
MX - Messico 14
PT - Portogallo 14
SC - Seychelles 14
PK - Pakistan 12
IR - Iran 11
AU - Australia 10
HU - Ungheria 9
NZ - Nuova Zelanda 9
AT - Austria 8
CL - Cile 8
CZ - Repubblica Ceca 8
TW - Taiwan 8
AR - Argentina 7
IL - Israele 5
MY - Malesia 5
EU - Europa 4
KR - Corea 4
SM - San Marino 4
CO - Colombia 3
DK - Danimarca 3
LU - Lussemburgo 3
MU - Mauritius 3
NO - Norvegia 3
SA - Arabia Saudita 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
CR - Costa Rica 2
EC - Ecuador 2
MD - Moldavia 2
PH - Filippine 2
RS - Serbia 2
TH - Thailandia 2
UZ - Uzbekistan 2
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BS - Bahamas 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
MT - Malta 1
RE - Reunion 1
TN - Tunisia 1
Totale 25.816
Salva come PNG Salva come JPEG
Città #
Southend 1.209
Singapore 907
Fairfield 851
Chandler 747
Milan 686
Ashburn 552
Rome 497
Princeton 439
Dong Ket 438
Woodbridge 432
Wilmington 396
Seattle 361
Houston 353
Santa Clara 329
Cambridge 323
Dublin 276
Boardman 274
Bologna 274
Ann Arbor 248
Berlin 208
Westminster 190
Florence 161
Turin 153
Dearborn 129
Sofia 129
Des Moines 124
Medford 118
Jacksonville 114
Naples 114
Padova 113
Nanjing 103
Jinan 83
Genoa 79
Beijing 65
Brescia 64
Lomé 63
Verona 59
Bari 58
Napoli 58
Olalla 57
Palermo 55
Redwood City 55
San Diego 52
Los Angeles 47
Tianjin 45
Jakarta 44
Guangzhou 43
Shenyang 43
Catania 42
Redmond 41
Hebei 40
Helsinki 40
Dallas 39
Changsha 36
Monza 35
Torino 35
Modena 34
Saint Petersburg 34
Shanghai 34
Ancona 32
Cagliari 32
Perugia 32
Abidjan 31
Genova 31
New York 31
Pescara 30
Amman 29
Parma 29
Taiyuan 29
Bergamo 28
Trento 28
Venice 28
Mülheim 27
Zhengzhou 27
Livorno 26
Lucca 24
Brussels 23
Hangzhou 23
Cesena 22
Falls Church 22
Hyderabad 22
Nanchang 22
Pisa 22
Gressoney-Saint-Jean 21
Haikou 21
Vasto 21
Jiaxing 20
Ningbo 20
Moscow 19
Mountain View 19
Trieste 19
Bern 18
Hong Kong 18
Reggio Emilia 17
Como 16
Gambolò 16
Paris 16
Chicago 15
Istanbul 15
London 15
Totale 13.584
Salva come PNG Salva come JPEG
Nome #
VALUTAZIONE DELL’ESPRESSIONE IMMUNOCITOCHIMICA DI CD117 IN PREPARATI CITOLOGICI DA MASTOCITOMA 3.066
UN CASO DI MASTOCITOMA CON INTERESSAMENTO MIDOLLARE IN UN CANE TRATTATO CON TERAPIA A BERSAGLIO MOLECOLARE 2.602
5-FLUORURACILE INTRAINCISIONALE NEL TRATTAMENTO ADIUVANTE DEI SARCOMI NON COMPLETAMENTE ESCISSI DELLE ESTREMITÀ: STUDIO PILOTA NEL CANE 1.146
Istiocitomi cutanei multipli che mimano micosi fungoide in un cane anziano: un dilemma diagnostico 1.115
Attività antitumorale di un nuovo farmaco in due casi di linfoma cutaneo felino non responsivi a lomustina 1.070
Oncologia medica veterinaria e comparata (a cura di Laura Marconato e Dino Amadori) 477
Emangiosarcoma splenico con quadro clinico atipico: l'importanza della collaborazione tra clinico e patologo 253
Comparison between May-Grünwald-Giemsa and rapid cytological stains in fine-needle aspirates of canine mast cell tumour: Diagnostic and prognostic implications 215
Feline large granular lymphocyte lymphoma: An Italian Society of Veterinary Oncology (SIONCOV) retrospective study 185
Comparison between May Grünwald-Giemsa and rapid stains in fine-needle aspirates of canine mast cell tumor: diagnostic and prognostic implications 171
Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009–2014) 140
Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision 139
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers 138
Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement 136
APPROCCIO MULTIMODALE AI TUMORI URETRALI DEL CANE:DESCRIZIONE DI 2 CASI 136
A retrospective analysis of chemotherapy switch suggests improved outcome in surgically removed, biologically aggressive canine haemangiosarcoma 131
Comparison of definitive-intent finely fractionated and palliative-intent coarsely fractionated radiotherapy as adjuvant treatment of feline microscopic injection-site sarcoma 130
ASSOCIATION BETWEEN WASTE MANAGEMENT AND CANCER IN COMPANION ANIMALS 128
Valutazione comparativa di attività proliferativa, differenziazione ed espressione immunoistochimica di CD117 nelle metastasi linfonodali rispetto al tumore primitivo nel mastocitoma del cane. 127
Adjuvant medical therapy provides no therapeutic benefit in the treatment of dogs with low-grade mast cell tumours and early nodal metastasis undergoing surgery 126
Chronic lymphocytic leukemia transformation into high-grade lymphoma: a description of Richter's syndrome in eight dogs 125
Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms 125
Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanoma 125
Prognostic impact of clinical, haematological, and histopathological variables in 102 canine cutaneous perivascular wall tumours 125
Espressione del recettore kit (CD117) nel mastocitoma del cane: confronto citologia-istologia in 26 casi. 124
Canine indolent and aggressive lymphoma: Clinical spectrum with histologic correlation 124
Analysis of prognostic factors associated with injection-site sarcomas in cats: 57 cases (2001-2007) 124
Prognostic significance of peripheral blood and bone marrow infiltration in newly-diagnosed canine nodal marginal zone lymphoma 124
Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumours: A prospective study 119
Comparison between May Grünwald-Giemsa and rapid stains in fine-needle aspirates of canine mast cell tumours: diagnostic and prognostic implications. 119
Adjuvant dose-intense versus metronomic chemotherapy for dogs with metastatic splenic hemangiosarcoma: a multi-institutional retrospective study. 118
Minimal residual disease in lymph nodes after achievement of complete remission predicts time to relapse in dogs with large B-cell lymphoma 118
Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs 118
Conformity and controversies in the diagnosis, staging and follow-up evaluation of canine nodal lymphoma: a systematic review of the last 15 years of published literature 113
Enhanced therapeutic effect of APAVAC vaccine in combination with dose-intense chemotherapy in dogs with clinically-advanced multicentric indolent B-cell lymphoma. 113
The impact of extirpation of non-palpable/normal-sized regional lymph nodes on staging of canine cutaneous mast cell tumours: A multicentric retrospective study 110
Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma 109
Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry 107
EGFR Expression is Predictive of Poor Prognosis in Feline Cutaneous Squamous Cell Carcinoma 106
Assessment of bone marrow infiltration diagnosed by flow cytometry in canine large B cell lymphoma: Prognostic significance and proposal of a cut-off value 105
Utility of flow cytometry in canine primary cutaneous and matched nodal mast cell tumor 103
Immunohistochemical characterization of therapeutic targets in canine bladder cancer 102
CANCER RISK LINKED TO WASTE CRISIS IN COMPANION ANIMALS AND THEIR ROLE AS MARKERS OF EFFECT: A HOSPITAL-BASED CASE-CONTROL STUDY IN NAPLES (ITALY) 102
Feline large granular lymphocyte lymphoma: an Italian Society of Veterinary Oncology (SIONCOV) retrospective study. 102
Sleeping Beauty: Anesthesia May Promote Relapse in Dogs With Diffuse Large B-Cell Lymphoma in Complete Remission After Chemo-Immunotherapy 102
Mastocitoma canino con coinvolgimento midollare: caratteristiche cliniche, patologiche ed opzioni terapeutiche nell’era dell’imatinib. 101
Prognosis following surgical excision in canine and feline malignant skin tumors: the role of the histological evaluation of margins. 101
EGFR overexpression in canine primary lung cancer: pathogenetic implications and impact on survival 101
Clinical relevance of simultaneous histopathological grading of canine cutaneous mast cell tumors at first presentation: a retrospective study on 386 cases. 100
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease 100
Environmental dust exposure and lung cancer in dogs: evidence for a link 100
Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour 99
Array-based comparative genomic hybridization analysis reveals chromosomal copy number aberrations associated with clinical outcome in canine diffuse large B-cell lymphoma 99
Diagnostic and prognostic value of TTF-1 (Thyroid Transcription Factor-1) immunohistochemistry in canine malignant lung tumors. 98
The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma 96
HYPOFRACTIONATED RADIOTHERAPY FOR MACROSCOPIC CANINE SOFT TISSUE SARCOMA: A RETROSPECTIVE STUDY OF 50 CASES TREATED WITH A 5 × 6 GY PROTOCOL WITH OR WITHOUT METRONOMIC CHEMOTHERAPY 96
EGFR expression and air pollution carcinogenesis in canine primary lung tumours 93
Nuovi aspetti della terapia a bersaglio molecolare: mastocitoma CD117 negativo responsivo ad imatinib. 92
Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma 92
Whole body computed tomographic characteristics of skeletal and cardiac muscular metastatic neoplasia in dogs and cats 91
Chemo-switch improves outcome in surgically-removed, biologically aggressive canine hemangiosarcoma. 90
CANINE NODAL MARGINAL ZONE LYMPHOMA: DESCRIPTIVE INSIGHT INTO THE BIOLOGICAL BEHAVIOUR. 90
Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference? 90
Long term follow-up and predictors of survival in dogs with mammary inflammatory carcinoma: a retrospective analysis of 43 cases 88
Canine medium macronucleated cell/ marginal zone lymphoma: description of 16 cases (2001-2008). 88
Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq 88
Splenic marginal zone lymphoma in 5 dogs (2001-2008) 87
Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide 87
Comparison of doxorubicin–cyclophosphamide with doxorubicin–dacarbazine for the adjuvant treatment of canine hemangiosarcoma 87
Comparative expression pathway analysis of human and canine mammary tumors 87
A retrospective study of flow cytometric characterization of suspected extranodal lymphomas in dogs 87
EGFR expression is predictive of a poor prognosis in feline cutaneous squamous cell carcinoma 85
Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma 85
Clinico-pathological features and treatment options for canine mast cell tumor with bone marrow involvement in the imatinib era: disappointment or challenge? 84
Postsurgical intra-incisional 5-fl uorouracil in dogs with incompletely resected, extremity malignant spindle cell tumours: a pilot study 84
Detection and Prognostic Relevance of Circulating and Disseminated Tumour Cell in Dogs with Metastatic Mammary Carcinoma: A Pilot Study 84
The European canine lymphoma network: A joining initiative to generate consensus guidelines for the diagnosis and therapy in canine lymphoma and research partnership 84
DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma 84
TTF-1 (Thyroid Transcription Factor-1) immunohistochemistry: diagnostic tool and malignancy marker in canine malignant lung tumours 83
COMPARISON OF A HYPOFRACTIONATED VERSUS A FULL-COURSE RADIOTHERAPY PROTOCOL FOR THE TREATMENT OF MICROSCOPIC CUTANEOUS MAST CELL TUMOURS IN DOGS. 83
Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline 83
Canine small clear cell/T-zone lymphoma: clinical presentation and outcome in a retrospective case series 82
Environmental risk factors for the development of oral squamous cell carcinoma in cats 81
Clinical Features and Outcome of 79 Dogs With Digital Squamous Cell Carcinoma Undergoing Treatment: A SIONCOV Observational Study 81
Oncologo medico, chirurgo e patologo: sinergia di tre figure professionali nella patologia neoplastica mammaria del cane. 80
Predictors of survival in dogs with mammary inflammatory carcinoma: a retrospective analysis of 43 cases (2003-2008) 80
Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma 80
An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors 80
The use of low-dose metronomic chemotherapy in dogs-insight into a modern cancer field 80
C-reactive protein, paraoxonase-1 and Alpha1-acid glycoprotein measurement in dogs with B- or T-cell lymphoma of different clinical stages. 79
CLINICAL OUTCOME OF DOGS WITH UROTHELIAL CARCINOMA TREATED WITH DOSE-INTENSE CHEMOTHERAPY VERSUS RADIO-CHEMOTHERAPY: A SINGLE-INSTITUTIONAL PROSPECTIVE UNBLINDED STUDY. 79
Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization 78
Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumours 77
Immunophenotype Predicts Survival Time in Dogs with Chronic Lymphocytic Leukemia 77
ESPRESSIONE DI EGFR E CANCEROGENESI DA INQUINAMENTO ATMOSFERICO NEI TUMORI POLMONARI DEL CANE 76
Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma 76
The Italian-Canine Cancer Biobank: Our 10-year challenge 76
First meeting of the European canine lymphoma group: Workshop: State of the art and comparative aspects in canine lymphoma: CH-Lugano, 22 June 2013 76
Predictors of long-term survival in dogs with high-grade multicentric lymphoma 76
Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology 75
Totale 19.249
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.778
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.082 0 0 0 0 539 654 610 689 602 366 239 383
2020/20214.492 703 262 230 183 320 252 220 271 460 289 268 1.034
2021/20223.941 413 181 273 221 411 366 138 288 190 239 600 621
2022/20234.840 430 554 270 531 397 420 207 375 732 213 432 279
2023/20243.170 226 367 234 252 204 271 238 203 147 288 371 369
2024/20254.075 570 1.198 774 731 802 0 0 0 0 0 0 0
Totale 26.489